Navigation Links
Device Can "Battle" Hospital Infections

An innovative University at Buffalo air sterilization technology that the U.S. Department of Defense is funding to protect troops on the battlefield //soon may be protecting hospital patients from deadly infections, thanks to recent funding from the New York State Office of Science, Technology and Academic Research (NYSTAR).

The funding comes as hospital-acquired infections, many of which are becoming increasingly difficult to treat, are on the rise.

The $674,900 grant from NYSTAR's Technology Transfer Investment Program will allow Buffalo BioBlower Technologies, the UB spin-off company that licensed the technology from UB, to develop a health-care prototype and take it into clinical trials.

"Receiving this NYSTAR grant is a major boost that will help ensure the success of Buffalo BioBlower," said Robert Genco, D.D.S., Ph.D., vice provost and director of the UB Office of Science, Technology Transfer and Economic Outreach (STOR). "We are very confident that in the next few years, companies like Buffalo BioBlower and others spun out of the university will make major contributions to economic development in Western New York."

The NYSTAR funding will support construction of a test room for evaluating a prototype for health-care applications.

The goal of the award is the development of a health-care division for Buffalo BioBlower Technologies, potentially creating up to 100 new jobs.

In tests funded by the Department of Defense and conducted last fall, the UB team has shown it can eradicate greater than 99.9999 percent of the spores of an anthrax surrogate in an airstream, according to the researchers.

"That's better than any conventional technology on the market." said James F. Garvey, Ph.D., UB professor of chemistry in the College of Arts and Sciences and co-founder and chief technical officer of Buffalo BioBlower Technologies with John Lordi, Ph.D., chief executive officer. Lordi is a research professor in the Department of Mechanical and Aerospace Engineering in the UB School of Engineering and Applied Sciences.

"We input one million live, active spores of a thermally resistant bacterium into the BioBlower and only one live spore comes out," said Garvey.

Through compressive heating and pressure oscillations that break up and kill pathogens, the dual-use technology called BioBlower can be expected to rapidly and continuously eradicate even the smallest of airborne biological pathogens, such as bacteria, spores, viruses, influenza including bird flu, pollen and mold.

That contrasts with the current conventional technology, HEPA (High-Efficiency Particulate Air) paper filters, which trap large airborne spores and need to be changed frequently, stored carefully and subsequently destroyed.

"With HEPA filters, the spores are still alive, once they're collected, waiting to infect somebody," Garvey said. "We kill them at the source."

The issue could not be more critical to the health-care market.

"The Centers for Disease Control says going to the hospital is the fourth biggest killer in this country," Garvey noted, because of the high incidence of hospital-acquired infections, a problem that he said is contributing rapidly to spiraling health-care costs.

In addition, the device could be made compact enough to turn an ordinary hospital room into an instant isolation unit, Garvey said, or as large as necessary to install in a building's HVAC unit to provide purified air throughout an entire facility.

Buffalo BioBlower's administrative office is in UB's New York State Center of Excellence in Bioinformatics and Life Sciences.

Lordi says that's a clear advantage, especially in light of the recent NYSTAR funding.

"We will benefit from interactions with the researchers in the Center of Excellence, as well as with all of the people in hea lth care on the Buffalo Niagara Medical Campus as we learn more about the whole problem of infection control," Lordi said.

(Source: Newswise)
'"/>




Related medicine news :

1. Injection supports Heart Devices
2. New Heart-Screening Device ,An Accurate Predictor Of Heart Disease
3. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
4. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
5. New Implantable Device That Can Keep The Heart Ticking
6. Making MRIs Safe for Patients With Implantable Heart Devices
7. Researchers Develop Device For Detecting Atherosclerotic Plaques
8. A Cheap Device to Stop Snoring from New Zealand
9. Scientists Concerned Over Increasing Malfunction Of Heart Devices
10. Device For Improving Bone Mass In Osteoporosis
11. Anti-Microbial Coating For Use Over Biomedical Devices Developed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... 2016 , ... Healthcare is in flux. The GOP wants ... mass media launching of story movements to highlight what's most unfair about healthcare. ... such a movement can generate the network power to improve healthcare policies in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, ... and around the greater Phoenix metropolitan region, is announcing a charity event to ... of the Homeless Youth Connection is to promote community awareness of the ongoing ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is ... by smoothing and tightening the skin of the face to create more youthful ... aging with very little downtime, Silhouette Instalift is a novel, minimally invasive facial ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
(Date:12/8/2016)... -- Mederi Therapeutics Inc . hat die behördliche Zulassung durch die ... Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the ... at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: